Kostelny et al., 2001 - Google Patents
Humanization and characterization of the anti‐HLA‐DR antibody 1D10Kostelny et al., 2001
View PDF- Document ID
- 639585389624785282
- Author
- Kostelny S
- Link B
- Tso J
- Vasquez M
- Jorgensen B
- Wang H
- Hall W
- Weiner G
- Publication year
- Publication venue
- International journal of cancer
External Links
Snippet
Abstract 1D10 is a previously described antibody that binds to cells from a majority of B‐cell malignancies. The current studies were designed to further evaluate the antigen specificity of 1D10 and its potential as an immunotherapeutic agent. Studies with transfectants and …
- 102000004965 antibodies 0 title abstract description 121
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kostelny et al. | Humanization and characterization of the anti‐HLA‐DR antibody 1D10 | |
| Maloney et al. | Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma | |
| JP5560301B2 (en) | Therapeutic and diagnostic methods and compositions targeting 4IG-B7-H3 and its corresponding NK cell receptor | |
| JP4843138B2 (en) | T cell inhibitory receptor composition and use thereof | |
| Tutt et al. | Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors | |
| Dreier et al. | Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody | |
| Macor et al. | In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab | |
| AU2024204218A1 (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| JP2021177768A (en) | New PD-1 immunomodulator | |
| US8268308B2 (en) | Means for the diagnosis and therapy of CTCL | |
| US6894149B2 (en) | Anti-HLA-DA antibodies and the methods of using thereof | |
| TW201639887A (en) | anti-DLL3 chimeric antigen receptor and method of use thereof | |
| JP2001502325A (en) | Methods and compositions for immunomodulation | |
| Germain et al. | MHC class I–related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells | |
| Li et al. | Construction and characterization of a humanized anti‐human CD3 monoclonal antibody 12F6 with effective immunoregulation functions | |
| JP2008502322A (en) | Compositions and methods for enhancing NK cell activity | |
| JPH01501201A (en) | antibody | |
| US6787638B1 (en) | Tumor specific human monoclonal antibodies and methods of use | |
| CN111971091A (en) | anti-BST 1 antibodies for prevention or treatment of myelodysplastic syndrome | |
| WO2024255692A1 (en) | Human epidermal growth factor 3 antibody, preparation method therefor, and use thereof | |
| Zhao et al. | Enhanced anti-B-cell tumor effects with anti-CD20 superantibody | |
| MXPA06009759A (en) | Target for b-cell disorders. | |
| EP4588939A1 (en) | Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer | |
| CN111132697A (en) | Pharmaceutical combination comprising anti-BST-1 antibodies and cytidine analogs | |
| Zhang | Three antibody-based immunotherapeutic modalities for malignancies |